Medtronic Plc MDT has been performing admirably in the bio-tech sector. The company
gained FDA clearance for
Hugo RAS in the vast urology market which will likely provide a significant boost going forward. Multiple asset management companies, including
Philadelphia Trust Co. and
Tema Etfs LLC, have
shifted their positions in Medtronic stocks, with various purchases and sales taking place. Crucially, Medtronic reported
strong Q2-2026 financial results and showcased increasing
enterprise growth drivers, triggering positive momentum. They've also announced a
cash dividend for the third quarter of the same fiscal year. Some experts have recently
upgraded Medtronic to a 'Buy' status due to its strong performance. Medtronic began the U.S. commercial launch of the MiniMed™ 780G system with the Instinct sensor and it's set to benefit from the
FDA clearance of the Hugo RAS System. There have been talks of Medtronic's earnings beat but the company continues to be seen as overvalued by some market watchers. As
FY26 gets underway, Medtronic is poised for a strong performance with expectations of increased profitability.
Medtronic Plc MDT News Analytics from Tue, 19 Aug 2025 07:00:00 GMT to Sat, 06 Dec 2025 13:54:06 GMT -
